Overview

Study of Radiolabeled Danicopan in Healthy Male Participants

Status:
Completed
Trial end date:
2017-10-15
Target enrollment:
Participant gender:
Summary
This was an open-label study to evaluate the absorption, distribution, metabolism, and excretion of radioactivity in healthy male participants following a single 150-milligram (mg) oral dose of carbon-14 ([14C])-ACH-014447 ([14C])-danicopan) containing approximately 100 microcuries (µCi) of [14C].
Phase:
Phase 1
Details
Lead Sponsor:
Alexion Pharmaceuticals
Collaborator:
Achillion, a wholly owned subsidiary of Alexion